TYTetsuji Yanase

Tetsuji Yanase

*This is an algorithmically generated author record based on publicly available information.

Tetsuji Yanase has a total of 59 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Drug Survival of Systemic Therapies for Psoriasis in the Western Japan Psoriasis Registry: 2024 Update

    by Noriko Tsuruta, Tetsuji Yanase, Eri Katayama, Chika Ohata, Takuya Miyagi, Kentaro Yonekura, Fumikazu Yamazaki, Kanami Saito, Yuko Higashi, Kazunari Sugita, et al.

    Drug survival is a useful composite measure reflecting treatment effectiveness, safety, convenience, and patient satisfaction in routine clinical practice. The Western Japan Psoriasis Registry (WJPR) is a prospective multicenter observational registry involving 34 dermatology centers in western Japan that continuously collects real‐world data on systemic therapies for patients with psoriasis. Yanase et al. previously reported drug survival in 1674 treatment episodes initiated between 2010 and 2020 within the WJPR; however, large‐scale real‐world data including recently introduced agents remain limited. We analyzed the drug survival of systemic therapies using data from 2251 patients and 4002 treatment episodes recorded in the WJPR between 2018 and 2024. Drug survival was assessed using the Kaplan–Meier method, and analyses were performed overall and stratified according to body mass index (BMI), psoriatic arthritis (PsA), previous biologic exposure, and sex. Multivariable Cox proportional hazards analyses were also performed for drugs with approved indications for PsA. Drug survival differed among treatments, with risankizumab demonstrating the most favorable persistence throughout the observation period, while guselkumab and ixekizumab also showed favorable drug survival. No significant differences in drug survival were observed according to BMI category. However, drug survival tended to be lower overall in patients with PsA, biologic‐experienced patients, and women. Among patients with PsA, bimekizumab maintained relatively favorable drug survival despite the generally lower treatment persistence observed in this subgroup. Multivariable analyses identified previous biologic exposure as the most consistent predictor of treatment discontinuation, whereas BMI was not independently associated with drug survival in any analyzed drug.

  • Real‐world safety and efficacy of biologics in elderly patients with psoriasis: A multicenter observational study

    by Chika Ohata, Hisataka Anezaki, Tetsuji Yanase, Eri Katayama, Sakae Kaneko, Kanami Saito, Mariko Yamane, Sei Nakamaru, Noriko Tsuruta, Fusako Okazaki, et al.

    Clinical trials of biologics have frequently excluded elderly patients, resulting in inadequate data on their safety and efficacy. Additionally, evidence of their safety and efficacy remains limited, despite some real‐world studies. To assess the safety and efficacy of biologics in elderly patients with psoriasis, we compared these outcomes in younger patients using data from the West Japan Psoriasis Registry (WJPR). The WJPR consists of approximately 30 facilities in Western Japan, including various healthcare settings. This study enrolled 1395 patients who participated in the 2022 follow‐up survey of the WJPR and were either using or had used biologics during the survey. These included 456 patients in the elderly group (≥65 years) and 939 patients in the younger group (p = 0.0234). Infectious diseases were more prevalent in the elderly group than the younger group; however, no significant difference in the frequency of infectious diseases was found between the two groups (p = 0.0807). Malignant neoplasms occurred significantly more frequently in the elderly group than in the younger group (p = 0.0169). Our results indicate a few concerns about infection when prescribing biologics to elderly patients. Biologics were effective for both elderly and younger patients. We found no significant differences in the proportion of patients with a body surface area score ≤3%, Physician's Global Assessment score 0/1, or Patient's Global Assessment score 0/1, as well as in the mean Dermatology Life Quality Index and the Itch Numerical Rating Scale between the younger and the elderly groups. Overall, our results confirm the appropriateness of using biologics in elderly patients with regard to safety and efficacy.


  • Survival rates of systemic interventions for psoriasis in the Western Japan Psoriasis Registry: A multicenter retrospective study

    by Tetsuji Yanase, Noriko Tsuruta, Kazuki Yamaguchi, Chika Ohata, Bungo Ohyama, Eri Katayama, Kazunari Sugita, Maki Kuwashiro, Aki Hashimoto, Kentaro Yonekura, et al.

    Psoriasis affects approximately 0.3% of the Japanese population. Recently, various effective systemic drugs have become available, and the continuation of a given treatment has become critical because of the chronic nature of psoriasis. Factors affecting drug survival (the time until treatment discontinuation) in psoriasis treatment include efficacy, safety, ease of use, and patient preference. In the present study, the authors retrospectively surveyed a multifacility patient registry to determine the real‐world evidence of the survival rate of systemic interventions for psoriasis treatment. Patients with psoriasis who visited 20 facilities in the Western Japan area between January 2019 and May 2020 and gave written consent were registered as study participants, and their medical history of systemic interventions for psoriasis (starting from 2010) was retrospectively collected and analyzed. The drugs investigated were adalimumab, infliximab, ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab, risankizumab, cyclosporine, and apremilast. When drugs were discontinued, the reasons were also recorded. A total of 1003 patients with psoriasis including 268 with psoriatic arthritis (PsA) were enrolled. In biologics, more recently released drugs such as interleukin 17 inhibitors showed a numerically higher survival rate in the overall (post‐2010) analysis. However, in the subset of patients who began treatment after 2017, the difference in the survival rate among the drugs was smaller. The reasons for discontinuing drugs varied, but a loss of efficacy against dermatological or joint symptoms were relatively frequently seen with some biologics and cyclosporine. The stratification of drug survival rates based on patient characteristics such as bio‐naive or experienced, normal weight or obese, and with or without PsA, revealed that bio‐experienced, obese, and PsA groups had poorer survival rates for most drugs. No notable safety issues were identified in this study. Overall, the present study revealed that the biologics show differences in their tendency to develop a loss of efficacy, and the factors that negatively impact the survival rate of biologics include the previous use of biologics, obesity, and PsA.


  • Clinical characteristics of patients with psoriasis with family history: A multicenter observational study

    by Chika Ohata, Hisataka Anezaki, Sakae Kaneko, Fusako Okazaki, Kotaro Ito, Yuki Matsuzaka, Satoko Kikuchi, Yuta Koike, Hiroyuki Murota, Takuya Miyagi, et al.

    Previous studies on family history of psoriasis showed that patients with a family history have an earlier onset of the disease, but such studies in Japan are still limited. To elucidate the characteristics of patients with familial psoriasis, we studied the family history of patients with psoriasis using the West Japan Psoriasis Registry, a multi‐institutional registry operated by 26 facilities in the western part of Japan, including university hospitals, community hospitals, and clinics. This study enrolled 1847 patients registered between September 2019 and December 2021, with 199 (10.8%) having a family history of psoriasis. Patients with a family history of psoriasis had significantly earlier onset of the disease than those without a family history. Furthermore, patients with a family history of psoriasis had significantly longer disease duration. Psoriatic arthritis (PsA) was significantly more common in patients with a family history (69/199, 34.7%) than in those without a family history (439/1648, 26.6%) (adjusted P = 0.023). A subanalysis of patients with PsA revealed a significant difference in the patient global assessment (PaGA) score in Fisher's exact test and adjusted test. The numbers of patients with PaGA 0/1 were 29 (43.3%) and 172 (39.9%) in patients with PsA with and without family history of psoriasis, respectively, whereas the numbers of patients with PaGA 3/4 were 13 (19.4%) and 145 (33.6%) in patients with PsA with and without family history of psoriasis, respectively. Other disease severity variables did not show a difference between the two groups. Our findings suggest that genetics play a larger role in the development of PsA than in the development of psoriasis vulgaris. Most cases of PsA occur in patients who already have psoriasis, therefore dermatologists should pay attention to joint symptoms, especially in patients with psoriasis who have a family history of psoriasis.


  • Prevalence of skin diseases and prognosis of atopic dermatitis in primary school children in populated areas of Japan from 2010 to 2019: The Asa Study in Hiroshima, Japan

    by Akio Tanaka, Naomasa Niimi, Masakazu Takahashi, Hiroyuki Takahashi, Keiji Nagata, Naruhisa Nishiyama, Hideki Noda, Takeshi Hara, Motoo Maeda, Yasuhiro Mizuiri, et al.

    Skin diseases are common in children. However, the prevalence of childhood skin diseases in Japan has not been reported extensively. In this study, dermatologists conducted face‐to‐face examinations of primary school children over a 10‐year period to determine the prevalence of each skin disease. Atopic dermatitis (AD, 12.3%) was the most common disease among first graders, followed by eczema other than AD (9.7%), molluscum contagiosum (1.9%), and verruca vulgaris (1.1%). Among sixth graders, acne vulgaris was most common (9.6%), followed by AD (8.9%), eczema other than AD (6.7%), and verruca vulgaris (3.1%). The prevalence of AD remained stable among first graders after 2010, at approximately 10%–15%, but it increased slightly among sixth graders. Of the 87 children who had AD in first grade, 51 (58.6%) were in remission in sixth grade. On the other hand, AD was diagnosed in 30 (4.5%) sixth graders who had been among the 665 children who did not have it in first grade. The more severe the symptoms were in first grade, the more likely a child was to still have AD in sixth grade, and the more severe the later symptoms tended to be. This study investigated recent trends in skin diseases in Japanese primary school children and found that the prevalence of some skin diseases differed between first and sixth graders. It was also found that children with moderate AD in first grade were more likely to be moderate in sixth grade than those with mild AD.